Emerging-market investors turn cautious
Russia's invasion of Ukraine has sparked a selloff in emerging markets as investors head for safe haven assets.
Many developing economies entered 2022 contending with high inflation, slowing growth and stretched public finances because of the pandemic, says The Economist. Then Russia invaded Ukraine. Now they can add soaring commodity prices into the mix: “Large importers of wheat and sunflower oil across north Africa and the Middle East, most notably Egypt” could be heading for hunger and civil unrest.
The war may also prompt companies and investors to take a more cautious approach to overseas investing in future for fear of further geopolitical upsets. That would mean less investment in emerging markets (EMs) – which are perceived as riskier – and steeper capital costs for local businesses.
High risk, low growth
“The start of the war sparked a sell-off across many EM financial markets,” says William Jackson of Capital Economics. This reflects “financial contagion” as investors turn towards safe haven assets. But EMs had been struggling before the invasion, with the MSCI Emerging Markets index falling more than 10% in the year to the end of February, even as the developed market equivalent gained more than 10%. That’s partly due to a regulatory crackdown in China, which accounts for almost one-third of the index.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Tighter US monetary policy is another headwind, says Jonathan Wheatley in the Financial Times. Higher interest rates on dollar assets tend to cause investors to pull cash from emerging market stocks and bonds. It also usually boosts the dollar, and a stronger greenback makes it more expensive for companies in emerging economies to raise and service dollar-denominated debt.
Emerging economies have less reliable legal and economic institutions than developed ones. Investors accept that when growth prospects are strong, but “the difference between the pace of growth in developing and advanced economies is set to narrow to its lowest level this century”. As David Lubin of Citi bank puts it, “without growth, it’s just [all] risk”.
Nevertheless, emerging markets look well-positioned, says Reshma Kapadia in Barron’s. Most have lower reliance on foreign borrowing and higher foreign exchange reserves than during previous periods of US monetary tightening. India’s foreign exchange reserves have more than doubled over the past decade. MSCI EM company profits “are expected to grow by 10.2% in 2022”, faster than the 8.9% predicted for US stocks.
That growth comes much cheaper too, with the index trading on 12 times 12-month forward earnings, compared with 19 in the US, “the widest valuation gap in nearly 20 years”. Brazil and Indonesia, which both stand to gain from the commodities boom, look intriguing bets.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
Christmas at Chatsworth: review of The Cavendish Hotel at Baslow
MoneyWeek Travel Matthew Partridge gets into the festive spirit at The Cavendish Hotel at Baslow and the Christmas market at Chatsworth
By Dr Matthew Partridge Published
-
Tycoon Truong My Lan on death row over world’s biggest bank fraud
Property tycoon Truong My Lan has been found guilty of a corruption scandal that dwarfs Malaysia’s 1MDB fraud and Sam Bankman-Fried’s crypto scam
By Jane Lewis Published
-
Why undersea cables are under threat – and how to protect them
Undersea cables power the internet and are vital to modern economies. They are now vulnerable
By Simon Wilson Published
-
India's stock market drops - why it's thrown investors into frenzy
Nifty 50, India's stock market index, has dropped 8% from a September record amid concerns of an economic slowdown and foreign investors pulling out
By Alex Rankine Published
-
Warren Buffet invests in Domino’s – should you buy?
What makes Domino's a compelling investment for Warren Buffet's Berkshire Hathaway, and should you buy the UK-listed takeaway pizza chain?
By Dr Matthew Partridge Published
-
Should you buy JPMorgan's top emerging market trust?
The JPMorgan Emerging Markets Trust fund has outperformed its benchmark over the long term and offers good value
By Max King Published
-
Is India still a good investment?
India's long-term story is compelling, but after a spectacular bull run, warning signs are starting to show. Is investing worth the risk?
By Cris Sholto Heaton Published
-
4Imprint makes a strong impression – should you buy?
4Imprint, a specialist in marketing promotional products, is the leader in a fragmented field
By Dr Mike Tubbs Published
-
Invest in Glencore: a cheap play on global growth
Glencore looks historically cheap, yet the group’s prospects remain encouraging
By Rupert Hargreaves Published
-
Should you invest in Trainline?
Ticket seller Trainline offers a useful service – and good prospects for investors
By Dr Matthew Partridge Published